Cargando…
25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial
BACKGROUND: Studies evaluating a relationship of vitamin D in patients with primary melanoma have consistently identified an inverse correlation with Breslow thickness, but an inconsistent impact on survival. Vitamin D in later stages of melanoma has been less studied. METHODS: Vitamin D was measure...
Autores principales: | Lipplaa, Astrid, Fernandes, Ricardo, Marshall, Andrea, Lorigan, Paul, Dunn, Janet, Myers, Kevin A., Barker, Emily, Newton-Bishop, Julia, Middleton, Mark R., Corrie, Pippa G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189120/ https://www.ncbi.nlm.nih.gov/pubmed/30033445 http://dx.doi.org/10.1038/s41416-018-0179-6 |
Ejemplares similares
-
A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update
por: Biswas, S, et al.
Publicado: (2008) -
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
por: Corrie, P G, et al.
Publicado: (2018) -
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
por: Corrie, P G, et al.
Publicado: (2019) -
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
por: Lee, R J, et al.
Publicado: (2018) -
Prediagnostic serum 25-hydroxyvitamin D and melanoma risk
por: Stenehjem, Jo S., et al.
Publicado: (2020)